Northera Confirmatory Trial Could Recruit Patients From Expanded Access Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA was unreceptive to Chelsea’s proposal to change endpoint in ongoing 306B study to provide confirmatory efficacy data for droxidopa in neurogenic orthostatic hypotension.